Related Experiment Video
Updated: Nov 27, 2025
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
[Integrative molecular pathology of cancer]
Thomas G P Grünewald1,2,3
1Abteilung Translationale Pädiatrische Sarkomforschung, Deutsches Krebsforschungszentrum (DKFZ), German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Deutschland. t.gruenewald@dkfz-heidelberg.de.
Abstract:
The field of molecular pathology has revolutionized our understanding of relevant oncogenic alterations in cancer and yielded new diagnostic tools and therapeutic approaches for personalized oncology, especially for malignancies of adulthood. However, many pediatric tumors, such as Ewing sarcoma, are characterized by a remarkable paucity of recurrent driver mutations, which are usually not suitable as drug targets. Despite the relative homogeneity of the somatic mutational profiles, these tumors nevertheless exhibit a relatively strong clinical heterogeneity, indicating additional modulating factors. In this regard, a recent study could demonstrate that the mode of action of the EWSR1-FLI1 (Ewing sarcoma breakpoint region 1-Friend leukema integration 1) fusion oncoprotein, which is pathognomonic for Ewing sarcoma, is influenced by inherited genetic variants in regulatory DNA elements, which may ultimately affect the course of the disease and also enable new therapeutic options. Thus, these investigations demonstrate in the Ewing sarcoma model that the function of a driver mutation needs to be interpreted in its germline context, which should be taken into account in an integrative approach by the molecular pathology of the future.
Insights
Pediatric tumors like Ewing sarcoma have few drug targets. Inherited genetic variants influence the EWSR1-FLI1 oncoprotein, impacting disease course and offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Pathology
- Genetics
Background:
- Molecular pathology advances personalized oncology, but pediatric tumors like Ewing sarcoma lack recurrent driver mutations for drug targeting.
- Ewing sarcoma exhibits clinical heterogeneity despite a generally uniform somatic mutational profile, suggesting other contributing factors.
- The EWSR1-FLI1 fusion oncoprotein is a hallmark of Ewing sarcoma.
Purpose of the Study:
- To investigate the influence of inherited genetic variants on the EWSR1-FLI1 oncoprotein's function in Ewing sarcoma.
- To explore how germline genetic variations modulate the impact of oncogenic drivers in pediatric cancers.
- To identify potential new therapeutic strategies by considering the germline context of cancer driver mutations.
Main Methods:
- Analysis of germline genetic variants in regulatory DNA elements.
- Investigating the functional impact of these variants on the EWSR1-FLI1 oncoprotein.
- Correlating genetic findings with clinical heterogeneity in Ewing sarcoma.
Main Results:
- Inherited genetic variants in regulatory DNA elements were found to influence the mode of action of the EWSR1-FLI1 oncoprotein.
- These germline variations can affect disease progression and clinical outcomes in Ewing sarcoma.
- The study highlights the importance of the germline genetic context for understanding oncogenic driver function.
Conclusions:
- The function of oncogenic drivers, like EWSR1-FLI1 in Ewing sarcoma, must be interpreted within the patient's inherited genetic background.
- Integrating germline genetics into molecular pathology offers novel therapeutic targets and personalized treatment strategies for pediatric cancers.
- Future molecular pathology approaches should adopt an integrative strategy considering both somatic and germline genetic information.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...